Cart summary

You have no items in your shopping cart.

COVID-19 & SARS-CoV S glycoprotein antibody

Catalog Number: orb669766

DispatchUsually dispatched within 5-10 working days
$ 531.00
Catalog Numberorb669766
CategoryAntibodies
DescriptionMouse monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein
Species/HostHuman
ClonalityMonoclonal
Clone NumberCR3022
Tested applicationsELISA, IF
ReactivityVirus
IsotypeIgG1
ImmunogenThe original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Concentration1 mg/ml
PurityPurified
ConjugationUnconjugated
TargetCOVID-19 & SARS-CoV S glycoprotein
UniProt IDP59594
StorageStore at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
Buffer/PreservativesPBS with 0.02% Proclin 300.
Alternative namesSpike protein, COVID19, COVID 19, S protein, SARS-
Read more...
NoteFor research use only
Application notesThis antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.
Expiration Date12 months from date of receipt.

Line graph illustrates about the Ag-Ab reactions using different concentrations of antigen and serial dilutions of COVID-19 & SARS-CoV S glycoprotein antibody

Line graph illustrates about the Ag-Ab reactions using different concentrations of antigen and serial dilutions of COVID-19 & SARS-CoV S glycoprotein antibody

Line graph illustrates about the Ag-Ab reactions using different concentrations of antigen and serial dilutions of COVID-19 & SARS-CoV S glycoprotein antibody

Submit a review

Filter by Rating

    • Star
    • Star
    • Star
    • Star
    • Star
    • 5 stars
    • Star
    • Star
    • Star
    • Star
    • Star
    • 4 stars
    • Star
    • Star
    • Star
    • Star
    • Star
    • 3 stars
    • Star
    • Star
    • Star
    • Star
    • Star
    • 2 stars
    • Star
    • Star
    • Star
    • Star
    • Star
    • 1 stars